Latest news with #PaulLaBarre
Business Wire
7 hours ago
- Health
- Business Wire
Polio Vaccination Campaign Planned in Afghanistan with PharmaJet
GOLDEN, Colo.--(BUSINESS WIRE)--Please replace the release dated August 19, 2025 with the following corrected version due to multiple revisions - removing mentions of WHO and UNICEF and all operational details which are subject to national authorities and partners agreement. The updated release reads: Polio Vaccination Campaign Planned in Afghanistan with PharmaJet ® Tropis ® ID Delivery System PharmaJet has been awarded a tender to support the first large-scale implementation of intradermal (ID) polio immunization in Afghanistan. PharmaJet's award builds on the successful implementation of Tropis for ID delivery in polio vaccination campaigns in Pakistan, Nigeria, and Somalia. The use of Tropis ID in polio vaccination campaigns has improved vaccine coverage, decreased immunization program costs, and increased acceptability. PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign in Afghanistan. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. Including Tropis ID fractional doses of inactivated polio vaccine (fIPV) in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages, prevent new WPV1 cases, and prevent local transmission. 'We are pleased to be supporting Afghanistan in their continued efforts to eradicate polio,' said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. 'We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability 1 previously seen with Tropis ID delivered fIPV in Pakistan, 1 Somalia, 2 and Nigeria 3.' Refer to Instructions for Use to ensure safe injections and to review risks. *NOTE: We regret that the content of this news release on August 19, 2025 was originally published without UNICEF/WHO consent. Operational details remain subject to national authorities and partners agreement. 1 Daly, C et al, Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February, 2020, Pages 1893-1898 2 Nouh, K et al, Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia, Springer Nature Volume 2 article number 16 (2024) 3 Biya, O et al, Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022, CDC Morbidity and Mortality Weekly report, November 24, 2023 / 72(47);1290–1291 About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn.
Business Wire
7 hours ago
- Health
- Business Wire
CORRECTING and REPLACING Polio Vaccination Campaign Planned in Afghanistan with PharmaJet
GOLDEN, Colo.--(BUSINESS WIRE)--Please replace the release dated Aug. 19, 2025 with the following corrected version due to multiple revisions - removing mentions of WHO and UNICEF and all operational details which are subject to national authorities and partners agreement. The updated release reads: Polio Vaccination Campaign Planned in Afghanistan with PharmaJet ® Tropis ® ID Delivery System PharmaJet has been awarded a tender to support the first large-scale implementation of intradermal (ID) polio immunization in Afghanistan. PharmaJet's award builds on the successful implementation of Tropis for ID delivery in polio vaccination campaigns in Pakistan, Nigeria, and Somalia. The use of Tropis ID in polio vaccination campaigns has improved vaccine coverage, decreased immunization program costs, and increased acceptability. PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign in Afghanistan. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. Including Tropis ID fractional doses of inactivated polio vaccine (fIPV) in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages, prevent new WPV1 cases, and prevent local transmission. 'We are pleased to be supporting Afghanistan in their continued efforts to eradicate polio,' said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. 'We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability 1 previously seen with Tropis ID delivered fIPV in Pakistan, 1 Somalia, 2 and Nigeria 3.' Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn.
Business Wire
a day ago
- Health
- Business Wire
WHO and UNICEF to Launch Polio Vaccination Campaign in Afghanistan with PharmaJet
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign sponsored by the National Emergency Operation Center (NEOC) Afghanistan, UNICEF, WHO, and other GPEI partners starting in August 2025. Focused on the Eastern region of Afghanistan, the campaign will deploy Tropis ID to administer 1.3 million fractional doses of inactivated polio vaccine (fIPV) to children ages 5 and under in parallel to oral polio vaccine (OPV) administration as part of a WHO-recommended strategy to boost humoral and mucosal immunity. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. This approach is expected to help increase immunization coverage, particularly in high-risk areas. The Technical Advisory Group (TAG) on polio eradication endorsed the Afghanistan program's 'Strategic Reset' to optimize site-to-site vaccination, while stressing the need for stronger leadership, community acceptance, and broad government engagement. Including Tropis ID fIPV in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages in the East, prevent new WPV1 cases in the East and South Regions, and prevent local transmission in other parts of the country. 1 'We are pleased to be partnering with UNICEF, WHO, and NEOC Afghanistan in their continued efforts to eradicate polio,' said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. 'We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability 2 previously seen with Tropis ID delivered fIPV in Pakistan, 2 Somalia, 3 and Nigeria 4.' Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About the NEOC Afghanistan NEOC Afghanistan is led by the Ministry of Public Health and the core members are WHO, UNICEF, BMGF, CDC, Rotary International, Core Group of Polio Project (CGPP), EPI manager and the National Polio Focal Point. About the Global Polio Eradication Initiative (GPEI) 5 The Global Polio Eradication Initiative is a public-private partnership led by national governments with six partners – the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention (CDC), the United Nations Children's Fund (UNICEF), Gates Foundation and Gavi, the vaccine alliance. Its goal is to eradicate polio worldwide. Launched in 1988 after the World Health Assembly passed a resolution to eradicate polio, the Global Polio Eradication Initiative, along with its partners, has helped countries to make huge progress in protecting the global population from this debilitating disease. As a result, the global incidence of polio has decreased by 99.9% since GPEI's foundation. An estimated 20 million people today are walking who would otherwise have been paralyzed by the disease, and more than 1.5 million people are alive, whose lives would otherwise have been lost. Now the task remains to tackle polio in its last few strongholds and get rid of the final 0.1% of polio cases including the two remaining endemic countries: Pakistan and Afghanistan.
Business Wire
2 days ago
- Health
- Business Wire
WHO and UNICEF to Launch Polio Vaccination Campaign
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign sponsored by the National Emergency Operation Center (NEOC) Afghanistan, UNICEF, WHO, and other GPEI partners starting in August 2025. Focused on the Eastern region of Afghanistan, the campaign will deploy Tropis ID to administer 1.3 million fractional doses of inactivated polio vaccine (fIPV) to children ages 5 and under in parallel to oral polio vaccine (OPV) administration as part of a WHO-recommended strategy to boost humoral and mucosal immunity. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. This approach is expected to help increase immunization coverage, particularly in high-risk areas. The Technical Advisory Group (TAG) on polio eradication endorsed the Afghanistan program's 'Strategic Reset' to optimize site-to-site vaccination, while stressing the need for stronger leadership, community acceptance, and broad government engagement. Including Tropis ID fIPV in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages in the East, prevent new WPV1 cases in the East and South Regions, and prevent local transmission in other parts of the country. 1 'We are pleased to be partnering with UNICEF, WHO, and NEOC Afghanistan in their continued efforts to eradicate polio,' said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. 'We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability 2 previously seen with Tropis ID delivered fIPV in Pakistan, 2 Somalia, 3 and Nigeria 4.' Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About the NEOC Afghanistan NEOC Afghanistan is led by the Ministry of Public Health and the core members are WHO, UNICEF, BMGF, CDC, Rotary International, Core Group of Polio Project (CGPP), EPI manager and the National Polio Focal Point. About the Global Polio Eradication Initiative (GPEI) 5 The Global Polio Eradication Initiative is a public-private partnership led by national governments with six partners – the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention (CDC), the United Nations Children's Fund (UNICEF), Gates Foundation and Gavi, the vaccine alliance. Its goal is to eradicate polio worldwide. Launched in 1988 after the World Health Assembly passed a resolution to eradicate polio, the Global Polio Eradication Initiative, along with its partners, has helped countries to make huge progress in protecting the global population from this debilitating disease. As a result, the global incidence of polio has decreased by 99.9% since GPEI's foundation. An estimated 20 million people today are walking who would otherwise have been paralyzed by the disease, and more than 1.5 million people are alive, whose lives would otherwise have been lost. Now the task remains to tackle polio in its last few strongholds and get rid of the final 0.1% of polio cases including the two remaining endemic countries: Pakistan and Afghanistan. 1 World Health Organization, Global Polio Eradication Initiative, Technical Advisory Group urges strong action to eradicate polio in Afghanistan, February 26, 2025 2 Daly, C et al, Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February, 2020, Pages 1893-1898 3 Nouh, K et al, Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia, Springer Nature Volume 2 article number 16 (2024) 4 Biya, O et al, Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022, CDC Morbidity and Mortality Weekly report, November 24, 2023 / 72(47);1290–1291 5 Global Polio Eradication Initiative, who we are:
Business Wire
01-05-2025
- Health
- Business Wire
Publication in Vaccine Highlights Fewer Adverse Events with PharmaJet Needle-free Intradermal Delivery compared to Needle and Syringe
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, today announced the publication of a study demonstrating the benefits of the PharmaJet Tropis needle-free system compared with N/S for ID administration of fractional dose poliovirus vaccine (fIPV). The study entitled Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba is published in Vaccine. 1 In Cuba, the routine immunization (RI) schedule for polio consists of two doses of fIPV administered at 4 and 8 months of age administered intradermally with N/S. However, ID administration with N/S is relatively uncomfortable, complex and requires specific training. Improper technique can result in reduced immunogenicity. 2 Tropis offers an easy to use, reliable technique that has been shown to improve coverage in Pakistan, 3 Somalia 4 and Nigeria, 5 where it has been used to vaccinate nearly 12 million children. Tropis is the first and only needle-free ID delivery technology to achieve World Health Organization (WHO) prequalification. The study measured acceptability, safety, and immunogenicity of Tropis compared to N/S administration with a total of 6,704 children vaccinated. Surveys were administered to parents/guardians (n=5260) and nurses (n=66) to evaluate satisfaction. Additionally, blood samples from vaccinated children were analyzed for neutralizing poliovirus antibody levels. The results indicated significantly fewer adverse events with Tropis (6%) than N/S (13%) (p =0.028), and Tropis was preferred over N/S by large margins by both parents (98%) and nurses (98.5%). Survey respondents cited ease of vaccination, diminished crying, and increased comfort as the benefits of Tropis. Of note, seroprevalence did not differ significantly between Tropis and N/S. This research collaboration between the Instituto Pedro Kourí (IPK) and the WHO was conducted to gain valuable insights that can be applied to curb the global circulating vaccine-derived poliovirus. Cuba has proven a useful resource and partner for polio eradication, acting as an incubator for testing new ideas and approaches. The WHO–Cuban collaboration, lasting for over 20 years, has been vital for the Global Polio Eradication Initiative (GPEI), making it possible to design innovative strategies, especially for the polio eradication endgame and for immunization policy development worldwide. 6 'These results highlight that Tropis results in fewer AEs than Mantoux technique and is more acceptable. This should be very encouraging to vaccine programs aiming to take advantage of ID delivery,' said Paul LaBarre, Vice President of Global Business Development, PharmaJet. 'The strong performance of Tropis ID delivery is consistent with results recently seen in WHO-sponsored polio campaigns in Pakistan, Nigeria, and Somalia where Tropis has been used to administer polio vaccinations to nearly 12 million children.' For more information visit the PharmaJet website About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About Cuba's role in the collaboration with the WHO and GPEI 2 Cuba's part in the continuing collaboration with the World Health Organization (WHO) has focused on issues relevant to policymaking for the ongoing global polio eradication effort. It has concentrated particularly on looking for answers to scientific questions that could not be answered elsewhere, taking into account Cuba's unique OPV vaccination program, conducted only twice annually, usually in February and April. Specifically, research has addressed several aspects of OPV and inactivated poliovirus vaccine (IPV), such as immunogenicity, adverse reactions and complications, persistence of Sabin virus in populations, the immunogenicity schedule and its affordability, number of doses needed, evaluation of new vaccines and devices, and booster response.
